An experimental peptide-based hepatitis C vaccine has shown promise in interim Phase II trial data, according to its developer Intercell.
The hepatitis C virus (HCV) is a major cause of chronic liver disease and 170m people worldwide carry the disease, however, currently there is no available vaccine.
Intercell's vaccine (IC41) comprises of eight T-cell antigens, combined with its first-generation poly-arginine adjuvant (IC30). It is designed to stimulate T-cell responses against HCV protein structures and reduce viral load.
Intercell said that the first data to be analysed from half of the 50 treatment-naïve study participants showed that its vaccine met the primary endpoint of achieving a statistically significant viral load (HCV-RNA) reduction.
read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment